Different medical institutions have selected different imported and domestic brand instruments: 38 domestic and 58 imported.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

Genialis recently announced a comarketing agreement with Thermo Fisher Scientific on data analysis for RNA sequencing.

Exact Sciences reported after the close of the market recently that its third quarter revenues rose 85 percent year over year, thanks to an 89 percent increase in testing volumes for its Cologuard colorectal cancer screening test.

LexaGene said recently that it has closed a previously announced financing round, grossing C$6.7 million (US$5.1 million).

Korean rare disease diagnostics firm 3billion said this week that it has raised $10 million in a Series B financing round.

Illumina and Qiagen recently announced a 15-year partnership to develop next-generation sequencing-based in vitro diagnostic kits, including companion diagnostics. The deal accompanied announcements that Qiagen CEO Peer Schatz would step dow

Genomic services provider Novogene has signed an agreement to develop a companion diagnostic for a cancer drug under development at Chipscreen Biosciences, the Chinese companies said today.

Thermo Fisher Scientific on Wednesday reported a 6 percent year-over-year increase in its third quarter revenues, driven by growth across most of its business segments.

Illumina reported after the close of the market on Thursday that its third quarter 2019 revenues grew 6 percent year over year.

Danaher on Thursday reported a 4 percent year-over-year increase in its third quarter revenues, which included a 6 percent rise in life sciences segment revenues and an increase in its diagnostics segment of almost 7 percent.

Qiagen reported after the close of the market on Wednesday that its third quarter revenues increased 1 percent year over year, missing analysts' consensus estimate.